Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape

In this podcast episode, Charles Rudin, MD, PhD, and Mark A. Socinski, MD, discuss current gaps and clinical needs for patients with relapsed ES-SCLC, and the evolving role of B7-H3–directed antibody–drug conjugates in the management of patients with ES-SCLC, including: - Clinical needs for relapsed ES-SCLC - Scientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLC - ADCs, T-cell engagers, chemotherapy-based approaches, maintenance strategies, and ongoing clinical trials for ES-SCLC - Recent efficacy and safety data for B7-H3–directed ADCs in ES-SCLC, including I-DXd - Personalization of care of patients with SCLC, including patient-specific factors influencing treatment - Case discussion of a patient with ES-SCLC requiring optimal next best treatment - Importance of enrolling patients in ongoing trials of investigational agents for patients with ES-SCLC **Presenters:** **Charles Rudin, MD, PhD** Cancer Center Director Memorial Sloan Kettering Cancer Center New York, New York **Mark A. Socinski, MD** Executive Medical Director AdventHealth Cancer Institute Orlando, Florida **Link to full program:** https://bit.ly/3UBEeYz Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.